![](\"https:\/\/mms.businesswire.com\/media\/20260609294223\/en\/2826476\/5\/SyntaxBio_logo_black.jpg\"){kind=logo}
<\/a><\/a>\nUnder the collaboration, the teams seek to define and develop an allogeneic pancreatic beta cell therapy for insulin-dependent diabetes based on patient needs. Syntax Bio plans to use its proprietary CellgorithmTM<\/sup> platform to guide induced pluripotent stem cells into beta cells. Mayo Clinic will provide expertise in pancreatic biology and functional testing in preclinical diabetes models to support regulatory-enabling studies and early clinical development.<\/p> \n\u201cThe collaboration reflects our belief that regenerative medicine must start with precise control over cell identity and function,\u201d said John Craighead, chief executive officer of Syntax Bio. \u201cBy combining our Cellgorithm platform with Mayo Clinic\u2019s translational and clinical expertise, we aim to accelerate the development of a next-generation cell therapy with transformative real-world benefits for patients with type 1 diabetes.\u201d<\/p> \nThe collaboration is focused on solving practical challenges in developing pancreatic cell therapies, including making sure the cells are the right type, function properly, can be produced consistently, and can be manufactured at scale.<\/p> \nThe teams will work in rapid development cycles, using results from functional testing to improve cell identity, maturity and performance. Programs that meet development milestones may advance through biopharmaceutical partnerships or other pathways to support further development and potential clinical testing.<\/p> \nCellgorithm technology simplifies stem cell differentiation by programming the sequence of gene activations needed to create specific cell types. The platform reduces the need for repeated manual interventions and has demonstrated the ability to generate target cell types in days or weeks rather than months<\/a>.<\/p> \nThis collaboration follows Syntax Bio\u2019s recent grant award from Breakthrough T1D<\/a> to advance pancreatic beta cell therapy for type 1 diabetes.<\/p> \nAbout Syntax Bio<\/b><\/p> \nSyntax Bio is a synthetic biology company programming the next generation of cell therapies. Its proprietary Cellgorithm\u2122 platform uses a CRISPR-based system to program and accelerate stem cell differentiation, transforming how regenerative medicines are discovered, developed, and manufactured. By replacing slow, labor-intensive differentiation processes with a rapid, programmable approach that mimics human development, Syntax Bio makes cellular generation more reliable and scalable at unprecedented speed, unlocking new possibilities across the biotechnology industry. Learn more at www.syntaxbio.com<\/a>.<\/p> \nMayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.<\/i><\/p>